About
Anatoly Kiyatkin is a Research Scientist in the Department of Pharmacology at Yale School of Medicine, Yale University. His research focuses on understanding the dynamics of receptor tyrosine kinase-mediated signaling networks, particularly how these networks influence cell fate decisions. Key areas of study include EGFR dimerization, signaling kinetics, and cross-talk between mitogenic and survival pathways. Kiyatkin holds a PhD in Biophysics from the Moscow Institute of Physics and Technology.
His work integrates computational modeling with experimental biology to dissect signal transduction mechanisms in health and disease, with implications for cancer and neurodegenerative disorders. Recent studies explore how mutations in EGFR affect glioblastoma progression and how ligands differentially stabilize receptor dimers to modulate signaling outputs.
Collaborations include projects with Boris Kholodenko, Mark Lemmon, and others, addressing topics like MAPK signaling, systems biology, and drug resistance mechanisms. Over 40 peer-reviewed publications since 2000 highlight his contributions to cell signaling dynamics, receptor engineering, and translational research in Alzheimer's disease vaccines.
